Alcon Acquires Neurotech Pharmaceuticals For $550 Million To Add FDA-Approved ENCELTO Retinal Therapy
· pulse2.com · popularity 19/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at pulse2.com →
Summary
Alcon has acquired Neurotech Pharmaceuticals for $550 million, expanding its retina portfolio with ENCELTO, the first and only U.S. FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2, or MacTel. The post Alcon Acquires Neurotech Pharmaceuticals For $550 Million To Add FDA-Approved ENCELTO Retinal Therapy appeared first on Pulse 2.0 .
Found in: Pulse 2.0. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 9.